China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS) reported a profit for its full year that Increased, from last year
The company's bottom line came in at RMB1.646 billion, or RMB1.5949 per share. This compares with RMB1.627 billion, or RMB1.5835 per share, last year.
The company's revenue for the period fell 1.9% to RMB11.000 billion from RMB11.211 billion last year.
China Resources Double-Crane Pharmaceutical Co.,Ltd. earnings at a glance (GAAP) :
-Earnings: RMB1.646 Bln. vs. RMB1.627 Bln. last year.-EPS: RMB1.5949 vs. RMB1.5835 last year.-Revenue: RMB11.000 Bln vs. RMB11.211 Bln last year.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.